EPIVIR-HBV
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIVIR-HBV is an oral small-molecule antiviral solution approved in 1998 for the treatment of chronic hepatitis B virus (HBV) infection. The drug belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and works by inhibiting HBV replication. It represents a foundational therapy in HBV management, though newer agents have since entered the market.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely optimizing mature-market profitability rather than driving growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EPIVIR-HBV offers limited career advancement potential given its LOE-approaching status and zero linked job openings. Roles on this product are typically maintenance-focused, emphasizing market access, managed care negotiations, and patient support programs rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on EPIVIR-HBV at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.